Wet Age-related Macular Degeneration Clinical Trial
— SPARROWOfficial title:
Study Comparing Early Extension of Aflibercept and Brolucizumab in Wet AMD (SPARROW)
Verified date | April 2024 |
Source | Berner Augenklinik |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease activity, thereafter following a T&E strategy with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this prospective explorative study is to test whether an early extension of treatment intervals without a loading phase is an option without compromising functional outcomes. Based on a superiority of Afl compared to Ran with regard to achieving a dry retina after one year and based on studies, but in the absence of real-life experience with Bro, it seems of interest to test how far Afl and Bro are comparable in terms of their potential to extend the treatment intervals over 12 months, the time to dryness of the retina, and number of injections. Also, it is of high clinical relevance to demonstrate efficacy with longer initial treatment intervals compared to the current possibly over-treating loading-phase with three four-weekly injections.
Status | Enrolling by invitation |
Enrollment | 80 |
Est. completion date | March 2028 |
Est. primary completion date | June 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Active MNV secondary to nAMD, going along with clinically significant vision loss - Patients aged 50 years or older of all sexes - Presence of IRF and/or SRF and/or subretinal hyperreflective material affecting the central subfield of the study eye on OCT - signed informed consent for this study prior to the screening visit - If possible: availability of a smartphone and willingness to perform self-testing with the Alleye app (soft criteria) Exclusion Criteria: - Any other cause of macular oedema - Structural damage to the macula precluding a visual potential - Optical media opacities not allowing an accurate performance of the protocol examinations - Any intraocular surgery within three months prior to inclusion and history of any vitreoretinal surgery - Advanced diabetic retinopathy potentially requiring any treatment within six months following inclusion or history of vitreal haemorrhage - Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea - History of IVT with anti-VEGF or corticosteroids at any time in the study eye - Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. - Significantly worse functional prognosis in the other eye or only eye - Women of childbearing potential not willing to use an effective method of contraception during treatment and until at least 3 months after the last treatment - Pregnant or lactating women - Any systemic auto-inflammatory and auto-immune disease requiring treatment - Treatment with high-dose corticosteroids (Prednisone equivalent >5mg/day), immunosuppressive or immunomodulatory or anti-proliferative agents for any reason - Inability or contraindications to undergo the investigated intervention |
Country | Name | City | State |
---|---|---|---|
Switzerland | Berner Augenklinik | Bern |
Lead Sponsor | Collaborator |
---|---|
Berner Augenklinik | medignition AG |
Switzerland,
Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 May 28. — View Citation
Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2181-2192. doi: 10.1007/s00417-020-05048-1. Epub 2021 Feb 2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of injections given until week 52 | number injections received by patient | 52 weeks | |
Secondary | Injections until week 104 | number injections received by patient | 104 weeks | |
Secondary | Number of treatment failures | number with treatment demand of less than 6 weeks at any time point | 52 weeks | |
Secondary | Number of treatment failures | number with treatment demand of less than 6 weeks at any time point | 104 weeks | |
Secondary | Time until drying of retina | mean interval until absence of intra- and subretinal fluid | 52 weeks | |
Secondary | Time until drying of retina | mean interval until absence of intra- and subretinal fluid | 104 weeks | |
Secondary | portion of eyes without disease activity | % patients with absence of intra- and subretinal fluid | 52 weeks | |
Secondary | portion of eyes without disease activity | % patients with absence of intra- and subretinal fluid | 104 weeks | |
Secondary | eyes under treatment intervals of =12 weeks | portion of eyes with stable disease under treatment intervals of =12 weeks | 52 weeks | |
Secondary | eyes under treatment intervals of =12 weeks | portion of eyes with stable disease under treatment intervals of =12 weeks | 104 weeks | |
Secondary | Change in visual acuity | change of VA in logRAD from baseline to week 52 | 52 weeks | |
Secondary | Change in visual acuity | change of VA in logRAD from baseline to week 104 | 104 weeks | |
Secondary | Change in central subfield thickness (CST) | change from baseline to week 52 | 52 weeks | |
Secondary | Change in central subfield thickness (CST) | change from baseline to week 104 | 104 weeks | |
Secondary | Portion of eyes gaining and loosing =5, =10, and =15 letters | change from baseline to week 52 | 52 weeks | |
Secondary | Portion of eyes gaining and loosing =5, =10, and =15 letters | change from baseline to week 104 | 104 weeks | |
Secondary | Maximal treatment interval extension | mean treatment interval extension | 52 weeks | |
Secondary | Maximal treatment interval extension | mean treatment interval extension | 104 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00138632 -
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Terminated |
NCT04594681 -
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT03585556 -
AAVCAGsCD59 for the Treatment of Wet AMD
|
Phase 1 | |
Completed |
NCT03362190 -
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
|
Phase 2 | |
Not yet recruiting |
NCT04564937 -
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
Terminated |
NCT02005133 -
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
|
N/A | |
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Completed |
NCT03748784 -
ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
Phase 1 | |
Recruiting |
NCT04468997 -
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1 | |
Completed |
NCT04685369 -
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
|
||
Recruiting |
NCT05297292 -
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
|
Phase 2/Phase 3 | |
Completed |
NCT03939767 -
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
|
||
Completed |
NCT03066258 -
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
|
Phase 1/Phase 2 | |
Terminated |
NCT01086761 -
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
|
Phase 1 | |
Recruiting |
NCT05727397 -
Efficacy and Safety of RC28-E Versus Aflibercept
|
Phase 3 | |
Completed |
NCT04884399 -
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
|
Phase 1 | |
Completed |
NCT04964089 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
|
Phase 3 | |
Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
Terminated |
NCT00139282 -
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
|
Phase 3 |